Ann: NTCELL reverses the progression of Parkinsons disease, page-33

Sorry Assen I cannot help you there I actually thought the first patient was at the 78 week mark.

Just reflecting on possible funding routes to complete the full 18 new patients clinical trials and onto full commercialisation. I am not sure exactly how the trial is being constructed but I understood it to be in series of 4 patients plus a couple of Placebo control patients. if that is the case then I still think we should probably not worry too much about Finance at this point . They can afford full commitment for trial duration for the first series of four patients . Why not just press on with those and if the results are as good and as immediate as the first clinical trials then they would know within two months that they really are onto something big . Then publish that progress and watch the financiers line up rather than give anything away now while the market cap and share price is so low. if the patience don't react as expected then you would question the benefit of ploughing on with the remaining patients anyway . Just my thoughts ( and no doubt will mean finance will get announced tomorrow - I could live with that to as long as it's not a giveaway!)